Boston Scientific's top-line growth has faded sharply, from roughly 22.8% YoY in 2025Q2 to 1.4% in 2026Q3, suggesting the organic engine may be weaker than earlier prints implied.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has decelerated to 1.4% in 2026Q3 from above 20% in 2025, while gross margin held at 66.7% and operating margin compressed to 19.1% from 22.8% in 2025Q4.
Boston Scientific Corporation is recognized for its leadership in minimally invasive medical devices, driving innovation in the healthcare sector.
Vanguard Group holds a significant 9.8% stake in Boston Scientific Corporation, indicating strong institutional confidence in the company.
With trailing and forward P/E ratios of 50.06 and 26.95 respectively, Boston Scientific Corporation presents compelling valuation opportunities for investors.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 28, 2026 | $0.73+0.4% vs $0.73 | $5.1B+1.0% vs $5.1B |
Q3 2026 Jul 29, 2026 | $0.86+3.0% vs $0.83 | $5.4B+1.2% vs $5.4B |
Q2 2026 Apr 22, 2026 | $0.80+1.5% vs $0.79 | $5.2B+0.6% vs $5.2B |
Q1 2026 Feb 4, 2026 | $0.80+2.4% vs $0.78 | $5.3B+0.1% vs $5.3B |
Boston Scientific (BSX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Boston Scientific's cyber disruption cuts Q3 growth and earnings, forcing lower 2026 guidance as management sees 2027 as the cycle's trough.
Boston Scientific's steep valuation discount faces a major test as earnings estimates weaken, core franchises lose momentum and key growth catalysts shift to 2028.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a $455 million collaboration with Boston Scientific Corporation (NYSE: BSX) to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System program. The VITALYST system is a next-generation, miniature heart pump intended to increase cardiac output and improve blood flow from the heart to the brain and other vital organs. It is designed to treat acute myocardial infarc.
Benchmark BSX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Boston Scientific Corporation (BSX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $42.75 | $63.54B | 17.79 | 19.87% | 16.56% | 13.74% | — | |
| $101.80 | $130.7B | 25.01 | 8.43% | 13.93% | 10.51% | 2.78% | |
| $102.14 | $58.81B | 57.77 | 11.55% | 15.3% | 9.65% | — | |
| $325.87 | $124.93B | 34.60 | 11.16% | 13.78% | 15.61% | 1.03% | |
| $105.59 | $20.43B | 26.33 | 7.2% | 8.96% | 6.05% | 0.91% | |
| $211.88 | $58.38B | 50.76 | -10.91% | 5.66% | 3.67% | 1.96% |
Boston Scientific Corporation (BSX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Boston Scientific Corporation (BSX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 28, 2026·SEC
Oct 7, 2026·SEC
Aug 26, 2026·SEC
Get notified when BSX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Boston Scientific Corporation (BSX) stock FAQ — growth, dividends, profitability & financials explained
Boston Scientific Corporation (BSX) reported $21.07B in revenue over the trailing twelve months. Revenue was $20.07B in fiscal year 2025. That is 1273% more than the $1.46B of fiscal year 1996.
Boston Scientific Corporation (BSX) grew revenue by 8.9% over the trailing twelve months, compared with the twelve months before.
Yes. Boston Scientific Corporation (BSX) earned $3.49B in net income over the trailing twelve months (a 16.6% net margin).
Boston Scientific Corporation (BSX) had a return on equity (ROE) of 13.7% over the trailing twelve months. That is in line with the market's typical 10-15%.
Boston Scientific Corporation (BSX) generated $3.33B in free cash flow over the trailing twelve months.
